Coronado Biosciences, Inc. announced the appointment of Kevin Horgan as its Chief Medical Officer. Dr. Horgan will oversee the company's clinical development programs and regulatory and medical affairs activities for its lead product candidates, TSO (Trichuris suis ova or CNDO-201) and CNDO-109. Prior to joining Coronado, he was Senior Vice President and Chief Medical Officer at Soligenix, Inc. since 2011.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.87 USD | +1.63% | -3.11% | -37.87% |
05-15 | Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q1 Revenue $13M | MT |
05-14 | Fortress Biotech Says First Patient Dosed in Phase 2 Study of Triplex | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.87% | 37.24M | |
-2.00% | 90.02B | |
-1.18% | 39.15B | |
-15.83% | 31.71B | |
+62.86% | 26.47B | |
-21.68% | 14.34B | |
-8.73% | 12.89B | |
-15.05% | 11.18B | |
-45.69% | 10.97B | |
+4.94% | 8.94B |
- Stock Market
- Equities
- FBIO Stock
- News Fortress Biotech, Inc.
- Coronado Biosciences Announces Appointment of Kevin Horgan as Chief Medical Officer